DISCOVERY AND DEVELOPMENTAL THERAPEUTICS (DDT)

发现和开发疗法（DDT）

• 批准号: 7944885
• 负责人: Fadlo Raja Khuri
• 金额: $ 7.98万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-07 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7944885
• 关键词: Antineoplastic Agents; Area; Biological; Biological Markers; Biology; Biomedical Research; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Immunology Science; Chemicals; Chemoprevention; Clinical Trials; Developmental Therapeutics Program; Environment; Epigenetic Process; Epithelial; Fostering; Funding; Goals; Hematologic Neoplasms; Institutes; Life Cycle Stages; Malignant Neoplasms; Mission; Modality; Molecular; Molecular Target; Nanotechnology; New Agents; Operative Surgical Procedures; Paper; Pathway interactions; Patients; Peer Review; Population Sciences; Prevention; Prevention approach; Public Health Schools; Publishing; Radiation; Reproduction spores; Research; Research Personnel; Science; Signal Pathway; Solid; Solid Neoplasm; Source; Testing; Tissues; Translating; Translations; base; cancer genetics; cancer immunotherapy; cancer therapy; college; drug development; drug discovery; innovative technologies; interest; medical schools; member; multimodality; nanotherapeutic; novel therapeutic intervention; prevent; programs; small molecule; therapeutic development; translational clinical trial; tumor

Program 3. Discovery and Developmental Therapeutics (DDT): The overall scientific goal of the Cancer Discovery and Developmental Therapeutics (DDT) Program is to enhance the discovery of new agents and advance their translation into the prevention and treatment of patients with cancer. The program has two full specific aims, and two major developing aims. The overall goal is to foster a highly collaborative team science environment, building on the existing strong ties with the MPB, CGE and CCPS Programs, to promote molecular target-based cancer drug discovery and to facilitate translational clinical trials for effective therapeutic development. To achieve this goal, the Program is organized with the following foci: (1) To identify small molecule modulators of tumor-addicted signaling pathways for cancer drug discovery; (2) To carry out mechanism-driven clinical trials for cancer drug development to rapidly move new agents to patients; (3) To translate discoveries in cancer immunology into mechanistically driven clinical trials enhancing the therapy of patients with hematologic malignancies and immuno-responsive solid tumors; (4) To test promising agents early in their life cycle in the multi-modality setting using mechanism-based clinical trials in conjunction with optimized chemo-radiation, radiation or surgery. We plan to achieve the goal of developing novel therapeutic approaches to the prevention and treatment of cancer through close intra- and inter-programmatic interactions by focusing on such areas as: (1) chemoprevention, (2) molecularly-targeted therapy, (3) new drug discovery, (4) biological interaction between epithelial and surrounding tissue, (5) nanotherapeutics, (6) cancer immunotherapy, (7) biomedical research platforms using innovative technology to prevent and treat tumors, and (8) translational multimodality research for advanced solid malignancies. The DDT Program comprises a diverse group of 45 members from 15 different departments within the School of Medicine, the School of Public Health and Emory College. The DDT Program has total peerreviewed program funding of $23 M, of which NCI funding represents $17.5M ($13.6M direct). In addition, there is a total of $1.9 M in non-peer-reviewed support from various sources. Program members have published a total of 535 papers during the last five years, of which 47% are intra-programmatic and 53% are inter-programmatic.

程序3.发现和发展治疗（DDT）：癌症的总体科学目标 发现和发展治疗（DDT）计划是为了加强新药物的发现， 将其转化为癌症患者的预防和治疗。该计划有两个完整的 具体目标和两大发展目标。总体目标是培养一支高度协作的团队 科学环境，建立在与MPB，CGE和CCPS计划现有的紧密联系的基础上， 促进基于分子靶点的癌症药物发现，并促进有效的转化临床试验 治疗发展为了实现这一目标，该方案的组织重点如下： 鉴定用于癌症药物发现肿瘤成瘾信号通路的小分子调节剂;（2） 开展机制驱动的癌症药物开发临床试验，以迅速将新药物推向 （3）将癌症免疫学的发现转化为机械驱动的临床试验 加强对恶性血液病和免疫应答性实体瘤患者的治疗;（4） 使用基于机制的临床试验，在多模态环境中在其生命周期早期测试有前途的药物。 试验结合优化的化学放射、放射或手术。 我们计划实现开发新的治疗方法来预防和治疗 通过方案内和方案间的密切互动，重点关注以下领域， (1)化学预防，（2）分子靶向治疗，（3）新药发现，（4）生物相互作用 上皮和周围组织之间，（5）纳米治疗，（6）癌症免疫治疗，（7）生物医学 利用创新技术预防和治疗肿瘤的研究平台，以及（8）转化多模式 晚期实体恶性肿瘤的研究 滴滴涕方案由来自联合国15个不同部门的45名成员组成， 医学院、公共卫生学院和埃默里学院。滴滴涕方案经过全面同行审查， 计划资金为2300万美元，其中NCI资金为1750万美元（直接1360万美元）。此外，本发明还提供了一种方法， 来自各种来源的非同行审查支持共计190万美元。计划成员有 在过去的五年里，共发表了535篇论文，其中47%是程序内的，53%是 跨方案。